JP Morgan Cazenove Reiterates Hikma Pharmaceuticals (HKMPF) Overweight Recommendation

JP Morgan Cazenove reiterated an "Overweight" rating on Hikma Pharmaceuticals (OTCPK:HKMPF) on November 7, 2025, with an average one-year price target of $33.13/share, implying a 31.21% upside from its $25.25 closing price. This positive outlook comes despite a projected 10.45% decrease in annual revenue to $2,880MM. Institutional interest remains robust, with total shares owned by institutions increasing by 38.93% to 8,508K and average portfolio weight rising by 24.30%, notably driven by significant increases from funds like John Hancock Disciplined Value International Fund, even as the overall number of reporting funds slightly decreased.

Analysis

JP Morgan Cazenove reiterated an 'Overweight' recommendation for Hikma Pharmaceuticals (OTCPK:HKMPF) on November 7, 2025, projecting a 31.21% upside to an average price target of $33.13/share from its $25.25 closing price. This bullish outlook comes despite a forecasted 10.45% decrease in annual revenue to $2,880MM, alongside a projected non-GAAP EPS of $2.12. The analyst's confidence suggests a focus beyond immediate top-line figures, potentially on profitability or future pipeline.

Institutional investor sentiment appears robust, with total shares owned by institutions increasing by 38.93% to 8,508K over the last three months. The average portfolio weight dedicated to HKMPF also rose significantly by 24.30% to 0.22%, indicating conviction among existing holders. This growth in institutional allocation occurred even as the number of reporting funds decreased by 2.44% (1 owner) in the last quarter.

A closer look at individual fund movements reveals divergent strategies; John Hancock Disciplined Value International Fund (JDIBX) notably increased its holdings by 62.34% to 2,430K shares, boosting its portfolio allocation by 83.23%. Conversely, Vanguard funds like VGTSX, VTMGX, VEU, and VEURX generally reduced their positions and portfolio allocations in HKMPF, with VGTSX decreasing shares by 4.37% and VTMGX by 3.48%.

Key Decisions for Investors

• Investors should assess the rationale behind JP Morgan's 'Overweight' rating, particularly how it reconciles with the projected 10.45% revenue decline, focusing on potential margin improvements, new product pipelines, or market share gains not immediately reflected in top-line forecasts.
• Given the significant increase in total institutional shares and average portfolio weight, investors should monitor continued institutional accumulation as a positive signal, while also understanding the differing strategies of funds like John Hancock (increasing) versus Vanguard (decreasing).
• With an implied 31.21% upside to the average price target, investors may consider the current risk/reward profile, but should also evaluate the range of analyst forecasts ($26.54 to $39.88) to gauge potential volatility and target confidence.